# Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis

> **NCT00489489** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 118 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Teriflunomide
- **DRUG:** Placebo (for Teriflunomide)
- **DRUG:** Interferon-β

## Key facts

- **NCT ID:** NCT00489489
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2012-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00489489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00489489, "Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00489489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*